Skip to Content
Merck
All Photos(1)

Documents

Y0001182

Captopril for system suitability

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Captopril, N-[(S)-3-Mercapto-2-methylpropionyl]-L-proline

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C9H15NO3S
CAS Number:
62571-86-2
Molecular Weight:
217.29
Beilstein:
477887
MDL number:
MFCD00168073
UNSPSC Code:
41116107
PubChem Substance ID:
329831295
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

captopril

manufacturer/tradename

EDQM

mp

104-108 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O

InChI

1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1

InChI key

FAKRSMQSSFJEIM-RQJHMYQMSA-N

Gene Information

human ... ACE(1636)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Captopril for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Angiotensin converting enzyme inhibitor. Inhibits the formation of angiotensin II, a bioactive peptide that stimulates angiogenesis and increases microvessel density.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Health hazard
GHS08

Signal Word

Danger

Hazard Statements

H341,H360F

Precautionary Statements

P201 - P308 + P313

Hazard Classifications

Muta. 2 - Repr. 1B

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Samir Attoub et al.
Annals of the New York Academy of Sciences, 1138, 65-72 (2008-10-08)
Lung cancer is the most common form of cancer in the world, and 90% of patients die from their disease. The angiotensin converting enzyme (ACE) inhibitors are used widely as antihypertensive agents, and it has been suggested that they decrease
Johannes J Kovarik et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 30(1), 115-123 (2014-08-12)
Blockade of the renin-angiotensin system (RAS) exerts beneficial effects in patients with mild-to-moderate chronic kidney disease, yet evidence suggesting a similar benefit in haemodialysis (HD) patients is not available. Furthermore, knowledge of the effects of RAS blockade on systemic RAS
Marie-Claude Racine et al.
Current hypertension reports, 4(3), 245-249 (2002-05-11)
With the introduction of more simple screening tests such as the aldosterone/renin ratio, the detection rate of primary aldosteronism has increased considerably. Until now, no reference values have been available for reporting the aldosterone/renin ratio using plasma aldosterone values expressed
A Schattner et al.
The American journal of the medical sciences, 322(4), 236-240 (2001-10-27)
Two elderly patients, treated with captopril for left ventricular dysfunction and diabetes, developed severe cholestatic jaundice for which no alternative explanation could be found. The jaundice resolved completely after discontinuation of the drug. A review of the literature identifies a
A O Nur et al.
International journal of pharmaceutics, 194(2), 139-146 (2000-02-29)
The development of oral sustained or controlled release dosage form of captopril has been an interested topic of research for a long period of time. Difficulties encountered with such topic based on the fact that the drug is freely water
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service